Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 9, 2019

View Archived Issues

Brain kinase induces spinal cord regeneration

Microfluidics method broadens human iPSC potential

Brain regulatory T cells potentiate neurological recovery

Oppilan Pharma initiates phase I study of OPL-002

Regulus announces clinical candidate nomination for RGLS-5579 for GBM

Oncolys BioPharma initiates phase II study of Telomelysin in combination with pembrolizumab

Patient enrollment begins in phase II study of CPI-613 in Burkitt lymphoma/leukemia

Kymab initiates phase II study of KY-1005 in atopic dermatitis

Patient recruitment ongoing in first-in-human study of IBI-101

Georgia State University describes new carbon monoxide-releasing molecules

Tarlige tablets receive approval in Japan for the treatment of peripheral neuropathic pain

Inovio initiates first-in-human study of DNA-encoded monoclonal antibody for Zika

The General Hospital Corp. patents new CYP1 inhibitors

Combining novel MCL-1 inhibitor with MEK inhibitors as promising new strategy in KRAS-mutant NSCLC

Genentech and Roche disclose IRAK-4 inhibitors

Medshine Discovery presents TLR8 agonists

CX-23, an NQO1-selective activated prodrug of triptolide, shows promise in preclinical models of HCC

Chinese researchers identify compounds for estrogen receptor-mediated diseases

Spero and Everest Medicines sign license and option agreements for SPR-206 and SPR-741 in Asia

Japan first to approve Evenity for osteoporosis

MediciNova opens enrollment in phase I/II study of MN-166 with temozolomide in GBM

Demser approved in Japan to improve catecholamine excess secretion in patients with pheochromocytoma

Japanese approval for Braftovi and Mektovi for unresectable melanoma with BRAF mutation

Wockhardt presents first clinical data for WCK-5222 in patients with renal impairment

IAVI initiates phase I trial of BG505 SOSIP.664 gp140 in HIV-uninfected subjects

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 9, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 3, 2026
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
Muscarinic M4 receptor positive allosteric modulators described in Neurosterix patent
BioWorld Science
Neurosterix Pharma Sarl has divulged 3-cyclopropylpyrazole derivatives acting as muscarinic M4 receptor positive allosteric modulators. They are reported to be...